Skip to main content
BIONIME logo

BIONIME — Investor Relations & Filings

Ticker · 4737 ISIN · TW0004737002 TW Manufacturing
Open in API
Filings indexed 1,735 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 4737

About BIONIME

www.bionime.com

Bionime Corporation is a biotechnology firm specializing in the research, design, and manufacturing of comprehensive blood glucose management systems. The company develops high-precision monitoring solutions for both personal home use and professional medical environments, including Blood Glucose Meters (BGM), Continuous Glucose Monitoring Systems (CGM), and Point-of-Care Testing (POCT). Under its proprietary brand, RIGHTEST, Bionime integrates medical, chemical, electronic, and precision machinery expertise to deliver products that rival international standards. A core component of its offering is a cloud-based management ecosystem powered by IoT digital solutions, which synchronizes medical data with patient care services. With over 480 core patents in CGM technology and a commitment to Industry 4.0 smart production, Bionime focuses on enhancing diabetes care through technical innovation and a human-centered approach to health monitoring.

Recent filings

Filing Released Lang Actions
115年第1季財務報告書 — 202601_4737_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled “合併財務報告暨會計師核閱報告” for the first quarter of 民國115 and 114, and contains KPMG’s review opinion followed by full consolidated interim financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement, and detailed notes). It covers a period shorter than a full fiscal year (Q1) and includes substantive financial data. Therefore, it is an Interim/Quarterly Report. Q1 2026
2026-05-14 Chinese
115年第1季海外子公司投資
Regulatory Filings Classification · 62% confidence The document is a one‐page extract from Taiwan’s Market Observation Post System (MOPS) Q1 reporting (“115年1季申報作業”) showing an equity‐method investment schedule for overseas subsidiaries. It does not constitute a full interim/quarterly report (no comprehensive financial statements or narrative analysis), nor is it an announcement of a report publication. Hence, it is best classified as a general regulatory filing (RNS) — a mandatory disclosure schedule that does not neatly fit any other specific category.
2026-05-14 Chinese
115年第1季大陸投資
Regulatory Filings Classification · 85% confidence The document is a standalone regulatory disclosure table of the company’s investments in Mainland China (大陸地區投資資訊), listing investee names, capital, cumulative investments, recognized gains, approval limits, and explanatory notes. It does not present a full annual or interim financial report, nor is it an announcement of an upcoming report. This fits the general regulatory filings category for Taiwan-listed companies’ compliance disclosures, classifying it as RNS.
2026-05-14 Chinese
公告本公司董事會通過115年第一季合併財務報告
Interim / Quarterly Report Classification · 91% confidence The document is a mandatory disclosure on Taiwan’s Public Information Observatory announcing that the board has approved the company’s first‐quarter consolidated financial report, and it provides substantive financial data for the period (revenue, profits, assets, liabilities, EPS, etc.). This fits the definition of an Interim/Quarterly Report rather than a mere publication notice or a short earnings release. Q1 2026
2026-05-13 Chinese
公告本公司「瑞特安活2連續葡萄糖監測系統 (RIGHTEST iFree2 CGM)」取得衛生福利部食藥署 (TFDA)核發第二等級醫療器材許可證核准通知
Regulatory Filings Classification · 90% confidence The document is a short corporate announcement posted on the public information observation station in Taiwan, notifying the market that the company’s medical device has received regulatory approval from the TFDA. It is not a financial report (Annual, Interim, Earnings, etc.), nor a board change, dividend, share transaction, or other specific category. It serves as a general regulatory material-event announcement and thus falls under the fallback category of Regulatory Filings (RNS).
2026-04-29 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 80% confidence The document is a brief tabular disclosure from Taiwan’s market observation post (“公開資訊觀測站”) detailing the company’s and subsidiaries’ month-end balances of loans and guarantees. It is not an annual or interim report, audit, dividend notice, or any other specific category but a routine regulatory disclosure. This falls under the general Regulatory Filings category (RNS).
2026-04-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.